Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.

Haematologica·2026
Same author

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Annals of hematology·2026
Same author

Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells.

Cancer immunology, immunotherapy : CII·2026
Same author

Aerosolized Pentamidine Is an Effective Prophylaxis for <i>Pneumocystis jiroveci</i> Pneumonia in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal of Korean medical science·2026
Same author

A novel anti-CD20, concabody, enhances immunotherapy efficacy by targeting MPZL1 and augmenting antibody-induced cell death.

Frontiers in oncology·2026
Same author

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Therapeutic advances in hematology·2026

Related Experiment Video

Updated: May 23, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Cellular immunotherapy using dendritic cells against multiple myeloma.

Thanh-Nhan Nguyen-Pham1, Youn-Kyung Lee, Hyun-Ju Lee

  • 1Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea.

The Korean Journal of Hematology
|April 6, 2012
PubMed
Summary
This summary is machine-generated.

Dendritic cell (DC) therapy shows promise for multiple myeloma (MM), but current results are disappointing. Enhancing DC function and targeting the tumor microenvironment are crucial for improving treatment efficacy.

Keywords:
Cellular immunotherapyCytotoxic T lymphocyteDendritic cellImmune responseMultiple myeloma

More Related Videos

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice
04:29

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice

Published on: July 1, 2022

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice
04:29

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice

Published on: July 1, 2022

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • Dendritic cells (DCs) are explored for immunotherapy in multiple myeloma (MM).
  • DC-based idiotype vaccination has shown limited clinical success in MM patients.
  • Improving DC migratory and cytokine-producing capacities is key for effective cancer vaccination.

Purpose of the Study:

  • To review strategies for enhancing the efficacy of dendritic cell vaccination in multiple myeloma.
  • To discuss the importance of targeting both myeloma cells and the tumor microenvironment.

Main Methods:

  • Review of current literature on dendritic cell-based therapies for multiple myeloma.
  • Analysis of factors influencing DC function, including migration and cytokine production.
  • Discussion of the role of the tumor microenvironment in MM progression and treatment resistance.

Main Results:

  • Current DC-based idiotype vaccination strategies for MM have yielded disappointing clinical results.
  • High migratory capacity and cytokine production in DCs are essential for potent anti-myeloma immune responses.
  • The tumor microenvironment significantly impacts MM cell growth and therapeutic resistance.

Conclusions:

  • DC-based therapies for MM require enhancement, potentially through combination with other tumor-associated antigens.
  • Strategies to boost DC potency and recruit them effectively are needed.
  • Novel treatments targeting both myeloma cells and the tumor microenvironment are essential for improved outcomes.